Technical Analysis for TRIL - Trillium Therapeutics Inc.

Grade Last Price % Change Price Change
F 10.42 -6.80% -0.76
TRIL closed down 6.8 percent on Friday, April 9, 2021, on 48 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical TRIL trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Crossed Above 20 DMA Bullish -6.80%
Fell Below 20 DMA Bearish 0.29%
BB Squeeze Ended Range Expansion 0.29%
Down 3 Days in a Row Weakness 0.29%
20 DMA Support Bullish -3.96%
Bollinger Band Squeeze Range Contraction -3.96%
Older End-of-Day Signals for TRIL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Trillium Therapeutics Inc. is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on tumor cells in acute myeloid leukemia (AML) and numerous other malignancies. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors. For more information visit: www.trilliumtherapeutics.com
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immunology Solid Tumors Immune System Treatment Of Cancer Monoclonal Antibody Cancer Immunotherapy Tumor Acute Myeloid Leukemia Antibody Drug Conjugates Fusion Protein Cancer Research Tumor Cell Cd20 CD47

Is TRIL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 20.96
52 Week Low 4.05
Average Volume 1,312,281
200-Day Moving Average 12.10
50-Day Moving Average 11.63
20-Day Moving Average 10.71
10-Day Moving Average 10.61
Average True Range 0.73
ADX 24.08
+DI 17.55
-DI 23.53
Chandelier Exit (Long, 3 ATRs ) 10.02
Chandelier Exit (Short, 3 ATRs ) 11.73
Upper Bollinger Band 11.66
Lower Bollinger Band 9.77
Percent B (%b) 0.34
BandWidth 17.60
MACD Line -0.24
MACD Signal Line -0.33
MACD Histogram 0.0954
Fundamentals Value
Market Cap 1.05 Billion
Num Shares 101 Million
EPS -2.55
Price-to-Earnings (P/E) Ratio -4.09
Price-to-Sales 10803.23
Price-to-Book 11.44
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.58
Resistance 3 (R3) 11.69 11.41 11.38
Resistance 2 (R2) 11.41 11.12 11.36 11.32
Resistance 1 (R1) 10.92 10.94 10.78 10.81 11.25
Pivot Point 10.64 10.64 10.58 10.59 10.64
Support 1 (S1) 10.15 10.35 10.01 10.04 9.59
Support 2 (S2) 9.87 10.17 9.82 9.52
Support 3 (S3) 9.38 9.87 9.46
Support 4 (S4) 9.27